Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Gross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Ocular Therapeutix (OCUL) Leases (2019 - 2026)

Ocular Therapeutix has reported Leases over the past 8 years, most recently at $6.5 million for Q1 2026.

  • For Q1 2026, Leases rose 11.44% year-over-year to $6.5 million; the TTM value through Mar 2026 reached $6.5 million, up 11.44%, while the annual FY2025 figure was $4.6 million, 21.98% down from the prior year.
  • Leases for Q1 2026 was $6.5 million at Ocular Therapeutix, up from $4.6 million in the prior quarter.
  • Over five years, Leases peaked at $8.0 million in Q4 2022 and troughed at $4.0 million in Q3 2022.
  • A 5-year average of $5.9 million and a median of $5.9 million in 2024 define the central range for Leases.
  • Biggest five-year swings in Leases: surged 71.53% in 2023 and later fell 21.98% in 2025.
  • Year by year, Leases stood at $8.0 million in 2022, then dropped by 19.52% to $6.5 million in 2023, then decreased by 8.14% to $5.9 million in 2024, then fell by 21.98% to $4.6 million in 2025, then skyrocketed by 40.04% to $6.5 million in 2026.
  • Business Quant data shows Leases for OCUL at $6.5 million in Q1 2026, $4.6 million in Q4 2025, and $5.3 million in Q3 2025.